Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma

SIMPLE SUMMARY: Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is the first oncolytic viral immunotherapy to be approved for the local treatment of unresectable metastatic stage IIIB/C–IVM1a melanoma. Its direct intratumoral injection aim to trigger local and systemic immunologic responses l...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrucci, Pier Francesco, Pala, Laura, Conforti, Fabio, Cocorocchio, Emilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003308/
https://www.ncbi.nlm.nih.gov/pubmed/33803762
http://dx.doi.org/10.3390/cancers13061383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003308/
https://www.ncbi.nlm.nih.gov/pubmed/33803762
http://dx.doi.org/10.3390/cancers13061383

Ejemplares similares